Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 6, 2014, Pages 2911-2916

  Chian, Song ^a   Li, Yin Yan ^a   Wang, Xiu Jun ^a   Tang, Xiu Wen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colorectal cancer; Luteolin; Nrf2; Oxaliplatin resistant cell lines; Sensitization

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CISPLATIN; DOXORUBICIN; LUTEOLIN; NFE2L2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; OXALIPLATIN; PLATINUM COMPLEX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUTEOLIN; MALE; MICE; MICE, INBRED C57BL; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899858360     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.6.2911     Document Type: Article

References (27)

1. Attoub S, Hassan AH, Vanhoecke B, et al (2011). Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol, 651, 18-25.
2. Bagli E, Stefaniotou M, Morbidelli L, et al (2004). Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res, 64, 7936-46.
3. Chen CC, Chu CB, Liu K J, et al (2013). Gene Expression Profiling for Analysis Acquired Oxaliplatin Resistant Factors in Human Gastric Carcinoma TSGH-S3 Cells: the Role of IL-6 Signaling and Nrf2/AKR1C Axis Identification. Biochem Pharmacol, 86, 872-87
4. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994). Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst, 86, 1517-24.
5. Conseil G, RG Deeley, Cole SP (2005). Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics, 15, 523-33.
6. DeNicola GM, Karreth FA, Humpton TJ, et al (2011). Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475, 106-9.
7. Gao AM, Ke ZP, Wang JN, et al (2013). Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis, 34, 1806-14.
8. Hu X F, Yao J, Gao SG, et al (2013). Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev, 14, 5231-5.
9. Itoh K, Mimura J, Yamamoto M (2010). Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal, 13, 1665-78.
10. Jeong WS, M Jun, A N. Kong (2006). Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal, 8, 99-106.
11. Konstantinopoulos PA, Spentzos D, Fountzilas E, et al (2011). Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res, 71, 5081-9.
12. Kwak MK, Kensler TW (2010). Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol, 244, 66-76.
13. Lin CW, Wu MJ, Liu IY, Su JD, Yen JH (2010). Neurotrophic and cytoprotective action of luteolin in PC12 cells through ERK-dependent induction of Nrf2-driven HO-1 expression. J Agric Food Chem, 58, 4477-86.
14. Lin Y, Shi R, Wang X, Shen HM (2008). Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets, 8, 634-46.
15. Magesh S, Chen Y, Hu L (2012). Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev, 32, 687-726.
16. McMahon M, Itoh K, Yamamoto M, et al (2001). The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res, 61, 3299-307.
17. Niture SK, Jaiswal AK (2012). Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem, 287, 9873-86.
18. O'Connell M J, Walworth NC, Carr AM (2000). The G2-phase DNA-damage checkpoint. Trends Cell Biol, 10, 296-303.
19. Pandurangan AK, Esa NM (2013). Dietary non-nutritive factors in targeting of regulatory molecules in colorectal cancer: an update. Asian Pac J Cancer Prev, 14, 5543-52.
20. Shim G S, Manandhar S, Shin DH, Kim TH, Kwak MK (2009). Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med, 47, 1619-31.
21. Sun GB, Sun X, Wang M, et al (2012). Oxidative stress suppression by luteolin-induced heme oxygenase-1 expression. Toxicol Appl Pharmacol, 265, 229-40.
22. Tang X, Wang H, Fan L, et al (2011). Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med, 50, 1599-609.
23. Wakabayashi N, Slocum SL, Skoko JJ, et al (2010). When NRF2 talks, who's listening? Antioxid Redox Signal, 13, 1649-63.
24. Wang JH, Du JP, Zhang YH, et al (2011). Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J Gastroenterol, 17, 3986-93.
25. Wang XJ, Hayes JD, Higgins LG, Wolf CR, Dinkova-Kostova AT (2010). Activation of the NRF2 signaling pathway by coppermediated redox cycling of para- and ortho-hydroquinones. Chem Biol, 17, 75-85.
26. Wruck CJ, Claussen M, Fuhrmann G, et al (2007). Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J Neural Transm Suppl, 72, 57-67.
27. Yoo NJ, Kim YR, Lee SH (2010). Expression of NRF2, a cytoprotective protein, in gastric carcinomas. APMIS, 118, 613-4.